What one share of YD Bio Limited holds
We are a publicly listed biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Our operations include DNA methylation-based oncology testing programs in the United States conducted under a LDT framework in collaboration with CLIA-certified and CAP-accredited laboratory partners.
YD Bio Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.01 |
|---|---|
| Profit | −$0.12 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.12 |
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | −$0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.01 | $0.00 | $0.00 | −$0.00 | — | — |
| 2024 | $0.01 | −$0.02 | $0.00 | −$0.02 | — | $0.10 |
| 2025 | $0.01 | −$0.12 | $0.02 | −$0.12 | — | −$0.04 |
Common questions about YD Bio Limited
How much does one share of YD Bio Limited earn?
Over its latest fiscal year, YD Bio Limited lost $0.12 for each share on $0.01 of sales.
Does YD Bio Limited pay a dividend?
YD Bio Limited didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is YD Bio Limited’s book value per share?
YD Bio Limited’s book value is negative (−$0.04 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of YD Bio Limited have?
Each share of YD Bio Limited has $0.08 of cash and investments and $0.00 of debt, as of December 31, 2025.
What is YD Bio Limited’s free cash flow per share?
−$0.12 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.